A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer

Inclusion Criteria:

- Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer

- Have been treated one time with a platinum-based chemotherapy and your disease has
come back at least six months after you completed treatment

- Are able to swallow tablets

- Have given written informed consent prior to any study procedures

- Have adequate blood counts, hepatic and renal function

- Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group
(ECOG) scale

- Have negative pregnancy test, and if participant is of child bearing potential must
use birth control while on study and for three months after stopping study drug

Exclusion Criteria:

- Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary
peritoneal cancer

- Are currently enrolled or discontinued less than 14 days from another clinical trial

- Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)

- Have taken certain medications or had grapefruit juice within 7 days of initial dose
of study drug, as levels of the study drug may be affected.

- Must not be pregnant or breastfeeding.

- Have malignancy or metastasis of the central nervous system

- Have borderline malignancy